TOKYO (Reuters) - German drug maker Bayer AG said on Monday that its drug Nexavar had been approved in Japan for the treatment of kidney cancer.
Last week, Japanese health authorities granted priority review status for Nexavar to treat liver cancer.
(Reporting by Edwina Gibbs)
© Thomson Reuters 2009 All rights reserved
|
|
Farmers endure 'harvest from hell'
Peshawar suffers new attack
Balloon boy parents plead guilty
Aamir, Kareena promote '3 Idiots'
9/11 suspects to be tried in NY
Agassi dishes on Barbra Streisand
Metal monk quits rock
APEC nations call for free trade
Putin puts his neck out for hip-hop
Madoff personal items for sale
Reuters.com:
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Labs |
Journalism Handbook |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
